Regencell Historical Income Statement
| RGC Stock | USD 5.00 0.46 8.42% |
Historical analysis of Regencell Bioscience income statement accounts such as Cost Of Revenue of 840.9 K, Total Operating Expenses of 5.4 M, Total Other Income Expense Net of 255.2 K or Tax Provision of 0.0 can show how well Regencell Bioscience Holdings performed in making a profits. Evaluating Regencell Bioscience income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Regencell Bioscience's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Regencell Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regencell Bioscience is a good buy for the upcoming year.
Regencell |
About Regencell Income Statement Analysis
Regencell Bioscience Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Regencell Bioscience shareholders. The income statement also shows Regencell investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Regencell Bioscience Income Statement Chart
Regencell Bioscience Holdings Income Statement is one of the three primary financial statements used for reporting Regencell's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Regencell Bioscience revenue and expense. Regencell Bioscience Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Regencell Bioscience's Selling And Marketing Expenses is projected to increase significantly based on the last few years of reporting. The current year's Reconciled Depreciation is expected to grow to about 929.4 K, whereas Depreciation And Amortization is forecasted to decline to about 658.1 K. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Regencell Bioscience. It is also known as Regencell Bioscience overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Regencell Bioscience operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Regencell Bioscience Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on Regencell Bioscience income statement and represents the costs associated with goods and services Regencell Bioscience provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Regencell Bioscience's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. At present, Regencell Bioscience's Selling And Marketing Expenses is projected to increase significantly based on the last few years of reporting. The current year's Reconciled Depreciation is expected to grow to about 929.4 K, whereas Depreciation And Amortization is forecasted to decline to about 658.1 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 7.6M | 6.3M | 5.6M | 5.4M | Cost Of Revenue | 604.4K | 769.7K | 885.1K | 840.9K |
Regencell Bioscience income statement Correlations
Click cells to compare fundamentals
Regencell Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regencell Bioscience income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 9.5K | 26.5K | 604.4K | 769.7K | 692.7K | 658.1K | |
| Selling General Administrative | 311.9K | 941.5K | 5.1M | 4.4M | 4.0M | 3.8M | |
| Other Operating Expenses | 812.4K | 1.4M | 7.6M | 6.3M | 5.6M | 5.4M | |
| Operating Income | (812.4K) | (1.4M) | (7.6M) | (6.3M) | (5.6M) | (5.4M) | |
| Ebit | (812.4K) | (1.4M) | (7.6M) | (6.3M) | (5.6M) | (5.4M) | |
| Ebitda | (802.9K) | (1.4M) | (7.0M) | (5.5M) | (5.0M) | (4.7M) | |
| Total Operating Expenses | 812.4K | 1.4M | 7.6M | 6.3M | 5.6M | 5.4M | |
| Income Before Tax | (812.4K) | (1.3M) | (7.6M) | (6.1M) | (5.5M) | (5.2M) | |
| Net Income | (812.4K) | (1.3M) | (7.4M) | (5.9M) | (5.3M) | (5.0M) | |
| Income Tax Expense | (1.0) | (34.6K) | (171.8K) | (191.2K) | (172.1K) | (163.5K) | |
| Selling And Marketing Expenses | 114.2K | 1.6K | 25.3K | 262.7K | 302.1K | 317.2K | |
| Net Income From Continuing Ops | (812.4K) | (1.3M) | (7.6M) | (6.1M) | (5.5M) | (5.2M) | |
| Research Development | 386.2K | 438.3K | 2.5M | 1.6M | 1.8M | 1.1M | |
| Reconciled Depreciation | 9.5K | 26.5K | 604.4K | 769.7K | 885.1K | 929.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.